Diagnosis and Management of Waldenstrom's Macroglobulinemia
Tóm tắt
To review the diagnostic criteria, prognostic factors, response criteria, and treatment options of patients with Waldenstrom's macroglobulinemia (WM).
A review of published reports was facilitated by the use of a MEDLINE computer search and by manual search of the Index Medicus.
WM should be regarded as a distinct clinicopathologic entity and confined to those patients with lymphoplasmacytoid lymphoma who have demonstrable serum immunoglobulin M monoclonal protein. Treatment decisions should rely on specific clinical and laboratory criteria. Initiation of therapy should not be based on serum monoclonal protein levels per se. The three main choices for systemic primary treatment of symptomatic patients with WM include alkylating agents (chlorambucil), nucleoside analogs (fludarabine and cladribine), and the monoclonal antibody rituximab. There are no data from prospective randomized studies to recommend the use of one first-line agent over another, although consideration of a patient's candidacy for autologous stem-cell transplantation (ASCT) should be taken into account to avoid stem cell–damaging agents. There are preliminary data to suggest that combinations of nucleoside analogs and alkylating agents with or without rituximab may improve response rates at the expense of higher toxicity.
WM is a distinct low-grade lymphoproliferative disorder. When therapy is indicated, alkylating agents, nucleoside analogs, and rituximab are reasonable choices. Several factors, including the presence of cytopenias, need for rapid disease control, candidacy for ASCT, age, and comorbidities, should be taken into consideration when choosing the most appropriate primary treatment.
Từ khóa
Tài liệu tham khảo
Waldenstrom J: Incipient myelomatosis or “essential” hyperglobulinemia with fibrinogenopenia: A new syndrome? Acta Med Scand 117:216,1944-222,
Fudenberg HH, Virella G: Multiple myeloma and Waldenstrom macroglobulinemia: Unusual presentations. Semin Hematol 17:63,1980-79,
Civit T, Coulbois S, Baylac F, et al: Waldenstrom's macroglobulinemia and cerebral lymphoplasmacytic proliferation: Bing and Neel syndrome—Apropos of a new case. Neurochirurgie 43:245,1997-249,
Farhangi M, Merlini G: The clinical implications of monoclonal immunoglobulins. Semin Oncol 13:366,1986-379,
Lindstrom FD, Hed J, Enestrom S: Renal pathology of Waldenstrom's macroglobulinemia with monoclonal antiglomerular antibodies and nephritic syndrome. Clin Exp Immunol 41:196,1980-204,
Morel P, Monconduit M, Jacomy D, et al: Prognostic factors in Waldenstrom macroglobulinemia: A report on 232 patients with the description of a new scoring system and its validation on 253 other patients. Blood 96:852,2000-858,
Buskard NA, Galton DAG, Goldman JM, et al: Plasma exchange in the long-term treatment of Waldenstrom's macroglobulinemia. Can Med Assoc J 117:135,1977-137,
Hampshire A, Saven A: Update of bolus administration of cladribine in the treatment of Waldenstrom's macroglobulinemia. Blood 102:402a,2003, (abstr)
Case DC, Ervin TJ, Boyd MA: Long term results and disease characteristics of patients with Waldenstrom's macroglobulinemia treated with the M-2 protocol. Blood 82:561a,1993, (abstr 2230)
Maloney DG, Sandmaier BM, Maris M, et al: Allogeneic hematopoietic cell transplantation for refractory Waldenstrom's macroglobulinemia: Replacing high-dose cytotoxic therapy with graft-versus-tumor effect. Blood 102:472b,2003, (abstr)
Treon SP, Shima Y, Preffer FI, et al: Treatment of plasma cell dyscrasias with antibody-mediated immunotherapy. Semin Oncol 26:97,1999-106, (suppl 14)
Weber DM, Gavino M, Huh Y, et al: Phenotypic and clinical evidence supports rituximab for Waldenstrom's macroglobulinemia. Blood 94:125a,1999, (abstr 551)
Ghobrial IM, Fonseca R, Greipp PR, et al: The initial “flare” of IgM level after rituximab therapy in patients diagnosed with Waldenstrom Macroglobulinemia: An Eastern Cooperative Oncology Group Study. Blood 102:448a,2003, (abstr)
Treon SP, Hansen M, Branagan AR, et al: Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical responses to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol (in press)
Owen RG, Rawstron AC, Osterborg A, et al: Activity of alemtuzumab in relapsed/refractory Waldenstrom's macroglobulinemia. Blood 102:644a,2003, (abstr)
Goy AG, Younes A, Mc Laughilin P, et al: A phase II study of proteasome inhibitor bortezomib in relapsed or refractory indolent or aggressive B-cell non-Hodgkin's lymphoma. Hematology J 5:S204,2004-S205, (suppl 2)